News Harm Reduction Therapeutics In The News The latest stories and news about Harm Reduction Therapeutics and naloxone FIRST SHIPMENT OF RiVive™ BRINGS LIFE-SAVING OVER-THE-COUNTER NALXONE NASAL SPRAY ONE STEP CLOSER TO THOSE WHO NEED IT MOST Dec 18, 2023 Open Society Supports an Innovative Model to Make Naloxone Easier to Access Amidst the U.S. Overdose Crisis Dec 12, 2023 Narcan Now Available Over-the-counter – What to Know Sep 5, 2023 Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution Aug 17, 2023 A new, cheaper naloxone is coming to pharmacy shelves, funded in part by Purdue Pharma’s bankruptcy Aug 17, 2023 FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE Aug 1, 2023 Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray Mar 24, 2023 Harm Reduction Therapeutics Inc. doesn’t have to make an advisory committee presentation for its proposal for an OTC naloxone nasal spray, but still must wait for a US Food and Drug Administration decision it’s confident will be for approval. The FDA on 1 March announced it cancelled the meeting of its Nonprescription Drug and Anesthetic and Analgesic Drug Products advisory committees to consider HRT’s new drug application for a 3-mg naloxone nasal spray scheduled 20 March. “The meeting is no longer needed,” the agency states in the announcement scheduled for publication in the Federal Register on 2 March. Mar 2, 2023 Drug companies could have made naloxone more accessible. Why didn’t they? Jan 23, 2023 Load More
